Abstract:Airway diseases were initially described by nonspecific patterns of symptoms, for example "dry and wheezy" and "wet and crackly". The model airway disease is cystic fibrosis, which has progressed from nonspecific reactive treatments such as antibiotics for airway infection to molecular sub-endotype, proactive therapies with an unequivocal evidence base, early diagnosis, and biomarkers of treatment efficacy. Unfortunately, other airway diseases lag behind, not least because nonspecific umbrella labels such as "asthma" are considered to be diagnoses not mere descriptions. Pending the delineation of molecular sub-endotypes in other airway disease the concept of treatable traits, and consideration of airway disease in a wider context is preferable. A treatable trait is a characteristic amenable to therapy, with measurable benefits of treatment. This approach determines what pathology is actually present and treatable, rather than using umbrella labels. We determine if airway inflammation is present, and whether there is airway eosinophilia which will likely respond to inhaled corticosteroids; whether there is variable airflow obstruction due to bronchoconstriction which will respond to β2-agonists; and whether there is unsuspected underlying airway infection which should be treated with antibiotics unless there is an underlying endotype which can be addressed, as for example an immunodeficiency. The context of airway disease should also be extrapulmonary comorbidities, social and environmental factors, and a developmental perspective, particularly this last aspect if preventive strategies are being contemplated. This approach allows targeted treatment for maximal patient benefit, as well as preventing the discarding of therapies which are useful for appropriate subgroups of patients. Failure to appreciate this almost led to the discarding of valuable treatments such as prednisolone. Educational aims: To use cystic fibrosis as a paradigm to show the benefits of the journey from nonspecific umbrella terms to specific endotypes and sub-endotypes, as a road map for other airway diseases to follow.Demonstrate that nonspecific labels to describe airway disease can and should be abandoned in favour of treatable traits to ensure diagnostic and therapeutic precision.Begin to learn to see airway disease in the context of extrapulmonary comorbidities, and social and environmental factors, as well as with a developmental perspective.

Change is in the air: key questions on the 'Treatable Traits' model for chronic airway diseases in primary care

Treatable Traits in Asthma: The importance of extra- pulmonary traits - GERD, CRSwNP, Atopic Dermatitis, and Depression/Anxiety

Treatable traits in pre‐COPD: Time to extend the treatable traits paradigm beyond established disease

Challenging the paradigm: moving from umbrella labels to treatable traits in airway disease

From treatable traits to GETomics in airway disease: moving towards clinical practice

Treatable Traits in Asthma: The Importance of Extrapulmonary Traits—GERD, CRSwNP, Atopic Dermatitis, and Depression/Anxiety

Treatable traits: a step closer to the “holy grail” of asthma control?

Treatable Traits in Elderly Asthmatics from the Australasian Severe Asthma Network: A Prospective Cohort Study

Precision medicine in united airways disease: A “treatable traits” approach

Treat to target approach for asthma

Treatable traits and exacerbation risk in patients with uncontrolled asthma prescribed GINA step 1–3 treatment: A nationwide asthma cohort study

Endotyping Chronic Respiratory Diseases: T2 Inflammation in the United Airways Model

Treatable Traits in Pregnant Women with Asthma

The Management of Extrapulmonary Comorbidities and Treatable Traits; Obesity, Physical Inactivity, Anxiety, and Depression, in Adults With Asthma

Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation

Microbes little helpers and suppliers for therapeutic asthma approaches

New therapies and management strategies in the treatment of asthma: patient-focused developments

Individual trajectory-based care for COPD: getting closer, but not there yet

A network meta-analysis of the association between patient traits and response to regular dosing with ICS plus short-acting β2-agonist reliever or ICS/formoterol reliever only in mild asthma

Moving from the Oslerian paradigm to the post-genomic era: are asthma and COPD outdated terms?

Asthma Endotypes and an Overview of Targeted Therapy for Asthma